These 3 Psychedelic Stocks Activated After Trump's Executive Order

These 3 Psychedelic Stocks Activated After Trump's Executive Order

Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.

Trump Psychedelic Executive Order Accelerates Industry Growth

Hypha Labs, Inc. (FUNI) Positioned to Lead with AI-Driven Production Technology

NRx Pharmaceuticals Responds to Executive Order on Mental Health Treatments

WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) said it supports an executive order signed April 18, 2026, directing federal agencies to accelerate research and regulatory pathways for treatments targeting serious mental illness, including psychedelic-based therapies. The order calls for expanded clinical research, increased data sharing, and expedited approval processes for drugs addressing conditions such as depression, post-traumatic stre…

FDA fast-tracks three psychedelic drugs

FDA moves to speed up psychedelic drug reviews The U.S. Food and Drug Administration is fast tracking three experimental psychedelic drugs for review as potential treatments for serious mental health conditions. The story summaries indicate the review acceleration applies to therapies aimed at…

StockWatch: Trump Order Lifts Psychedelic Drug Shares

Stocks of most publicly traded psychedelic drug developers jumped when President Donald Trump signed Executive Order 14401, directing the FDA and other federal agencies to accelerate research and improve access to psychedelic drugs, citing their potential as promising treatments for serious mental illnesses. Among its provisions, the order directs the FDA to provide Commissioner’s National Priority Vouchers (CNPVs) to “appropriate” psychedelic d…